Myovant Sciences Ltd
NYSE:MYOV
Myovant Sciences Ltd
Revenue
Myovant Sciences Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Myovant Sciences Ltd
NYSE:MYOV
|
Revenue
$379.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Revenue
$6.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Revenue
$1.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Revenue
$27m
|
CAGR 3-Years
37%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Revenue
£249.4m
|
CAGR 3-Years
102%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Revenue
£673.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
Myovant Sciences Ltd
Revenue Breakdown
Breakdown by Geography
Myovant Sciences Ltd
Breakdown by Segments
Myovant Sciences Ltd
Total Revenue:
231m
USD
|
Collaboration Agreement:
121.7m
USD
|
Amortization Of Upfront Payment:
83.9m
USD
|
Amortization Of Regulatory Milestone:
21.1m
USD
|
Revenue Recognized Upon Completion Of Delivery:
16.7m
USD
|
See Also
What is Myovant Sciences Ltd's Revenue?
Revenue
379.1m
USD
Based on the financial report for Dec 31, 2022, Myovant Sciences Ltd's Revenue amounts to 379.1m USD.
What is Myovant Sciences Ltd's Revenue growth rate?
Revenue CAGR 1Y
91%
Over the last year, the Revenue growth was 91%.